ALLARITY THERAPEUTICS INC (ALLR) Stock News

NASDAQ:ALLR - US0167445008 - Common Stock

1.6 USD

+0.06 (+3.9%)

Last: 9/2/2025, 8:00:00 PM

1.59 USD

-0.01 (-0.62%)

After Hours: 9/2/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALLR Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill - Mentions: NBY EPIX MODV NVNO ...

News Image

These stocks have an unusual volume in today's session

7 days ago - By: Chartmill - Mentions: SATS EPIX DOGZ WORX ...

News Image

Top stock movements in today's session.

5 days ago - By: Zacks Investment Research - Mentions: BSX

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

7 days ago - By: Benzinga - Mentions: NBY BOLT EPIX RMTI ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

7 days ago - By: Chartmill - Mentions: NIO OPEN EPIX TLRY ...

News Image

Check out the stocks that are attracting the most attention and driving market activity.

7 days ago - By: Benzinga - Mentions: EPIX WORX THAR NLSP ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

8 days ago - By: Chartmill - Mentions: SATS EPIX DOGZ WORX ...

News Image

Tuesday's session: top gainers and losers

8 days ago - By: Chartmill - Mentions: GTI SATS UUUU EPIX ...

News Image

Traders are paying attention to the gapping stocks in Tuesday's session.

8 days ago - By: Chartmill - Mentions: SATS EPIX MRKR PACK ...

News Image

Tuesday's pre-market session: top gainers and losers

8 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

8 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

18 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

18 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Changes to Board of Directors

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Changes to Board of Directors

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025